-
From Complex Statistics to Clinically Meaningful Insights: Interpreting Results in Meta-Analyses of Continuous Outcomes
Sep 9, 2025, 16:22 PM -
Reducing External Plasma Dependency: Impact for the Portuguese National Health Service
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness and Impact of Nirmatrelvir/Ritonavir in Reducing Hospitalizations Among Elderly COVID-19 Patients in Sweden
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness as Part of the German AMNOG Process Analyzing the 2025 SVR Proposal and Its Implementation Challenges
Sep 9, 2025, 16:22 PM -
Ischemic Stroke in Europe: Incidence Trends Over Three Decades (1991-2021)
Sep 9, 2025, 16:22 PM -
Evaluating Bayesian Borrowing Methods for Treatment Effect Extrapolation: A Simulation-Based Study
Sep 9, 2025, 16:22 PM -
The Hidden Clinical and Economic Costs of PPI Treatment Failures in Severe Erosive Esophagitis
Sep 9, 2025, 16:22 PM -
Review and Horizon Scanning of Advanced Therapy Medicinal Products in Slovenia: Registration, Reimbursement, and Future Pipeline
Sep 9, 2025, 16:22 PM -
Modeling Price Premiums of Oncology Drugs in Germany: A Cross-Validated Analysis Using XGBoost
Sep 9, 2025, 16:22 PM -
Equivalence of Measurement Properties of the Dermatology Life Quality Index (DLQI) Across 13 European Countries
Sep 9, 2025, 16:22 PM -
Patient Involvement in Health Technology Assessment: A Global Review of Practices, Purposes, and Pathways
Sep 9, 2025, 16:22 PM -
Treatment Preferences in Adults With Chronic Spontaneous Urticaria in Italy: Insights From the CHOICE-CSU 2 Study
Sep 9, 2025, 16:22 PM -
Identifying Dogs to Be Screened for Canine Chronic Kidney Disease (cCKD)
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of First-Line Lorlatinib for ALK-Positive Advanced NSCLC in the UK
Sep 9, 2025, 16:22 PM -
Mapping the Use of Capability Measures ICECAP-A and O in Economic Evaluations
Sep 9, 2025, 16:22 PM -
Comparison of the Environmental Impact of Subcutaneous vs. Oral Therapies
Sep 9, 2025, 16:22 PM -
Cost-Minimization Analysis and Economic Impact in EGPA: Evidence From MANDARA
Sep 9, 2025, 16:22 PM -
Premature Mortality and Lost Productivity Due to HPV-Related Cancers in Europe
Sep 9, 2025, 16:22 PM -
Assessment of the Cost Utility of Palivizumab for Preventing Severe Respiratory Syncytial Virus (RSV) Infection in Preterm Infants Born 29-35 Weeks' Gestational Age in the Philippines
Sep 9, 2025, 16:22 PM -
OncoLlama: Quantifying Cancer Inequalities at Population Scale Using Large Language Models for Clinical Text Abstraction
Sep 9, 2025, 16:22 PM
